Project Summary:
- Low-cost, point-of-care device for ultra-sensitive malaria diagnosis and drug resistance screening using the advanced, freeze-dried synthetic biology platform SHERLOCK.
- The project’s goals are to complete development and testing in two years.
To eliminate malaria in coming decades, new ultra-sensitive diagnostics will be needed to detect both drug resistance and latent reservoirs in asymptomatic individuals. Standard diagnostics used in the field cannot diagnose low-level infections, and the only assays with sufficient sensitivity (such as PCR) are poorly equipped for mass surveillance. In addition, no available test can simultaneously detect the presence of infection and drug resistance. This project will develop a low-cost, point-of-care device for ultra-sensitive malaria diagnosis and drug resistance screening using the advanced, freeze-dried synthetic biology platform SHERLOCK. The project’s goals are to complete development and testing in two years.
